Replies to post #197867 on Enzolytics Inc (ENZC)

[Valuator2]

I suspect you and I-glow know that what matters is the ownership of the rights to make, produce, use and sell, etc. under protection of a patent, not the actual ownership of a patent itself. JMHO. In fact, once an exclusive right is granted (assigned), the owner typically has no rights other than those reserved in the terms of the assignment. JMHO. So, to keep saying that ENZC doesn't own the patents may be true, but it is misleading because what they do own are the rights to those patents according to the licensing documents (assignments), assuming the documentation matches ENZC's representations. JMHO.

In this case, Harry Z's trust has assigned those rights to VIRO, which was and still may be a subsidiary of ENZC. Those assignments and an application for a multiple sclerosis patent assigned by Harry individually are attached to the BCA as exhibit 8. Note: the multiple sclerosis application has been reported in the ENZC reports as a provisional patent application, but the assignment is for "U.S. Application No. 63/123,341" filed 12/9/2020 and is a different number than the provisional patent application. Presumably, the new application was filed after the provisional expired. JMHO.

If you can find that these assignments are not legitimate, then you may have something, and I might agree with you, otherwise IMO you're talking BS about the patents and what ENZC or VIRO own.

(1) U.S. Patent No. 7,479538, Irreversibly - Inactivated pepsinogen fragment and
Pharmaceutical composition the same for detecting preventing and treating IIlV; U.S. Patent
No. 8,066982, Irreversibly - Inactivated pepsinogen :fragment and Pharmaceutical composition
compressing the same for detecting preventing and treating HIV (herein the "Licensed
Patent"), including all patents issuing therefrom and any foreign counterparts thereof;

WHEREAS Licensee wishes to license the Licensed Patent and Licensor is willing to grant to
Licensee a license to the Licensed Patent on the terms and conditions set forth in this Agreement.

(2) Harry individually assigned the patent application No.63/123,341 for multiple sclerosis, which has been disclosed in ENZC reports as the following and, to my knowledge, never updated for the new application number JMHO: https://www.otcmarkets.com/otcapi/company/financial-report/398912/content
O

n December 9, 2020 the company filed a provisional patent with the U.S. Patent Office for an Immunotherapy
treatment of Multiple Sclerosis developed by Harry Zhabilov, titled NUCLEAR PROTEINS ISOLATED FROM
MAMALIAN SPINAL CORD (SCNP) IMMUNE FACTOR, Ser. No. 62/123341. The Company received confirmation of
filing from the U.S. Patent Office on December 10, 2020. On January 19, 2021 the Company announced the receipt
for the Multiple Sclerosis Patent Application.